Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX11 Food Effect PK Study in Healthy Participants
NCT07349381Phase 1Completed
- Sponsor
- Vincentage Pharma Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VCT220 in obesity and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Vincentage Pharma Co., Ltd. Primary endpoints: Area Under the Concentration-time curve from 0 to 24 hour, Maximum Observed Concentration and 1 more. Started Mar 2026; status: completed.
02
Drugs
VCT220
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07349381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349381.